Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2026Journal of Medicinal Chemistry

Inhibitors of Ectonucleotidase CD39 for Immunotherapy of Cancer and Infections─Recent Developments and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChunyang BiFSFlorian SchwermerLTLu Tang

Discussion

Loading...

Member takes

Overview

Recent developments in CD39 inhibitors enhance immunotherapy effectiveness in cancer, suggesting promising therapeutic potential.

Key Points

  • The study examines the role of CD39 as a purinergic immune checkpoint in cancer immunotherapy and explores potential inhibitors.
  • Discussed non-nucleotidic and nucleotide-derived CD39 inhibitors
  • Presented structural insights and current clinical studies
  • Outlined strategies for combination therapy
  • CD39 inhibition increases ATP levels, reducing adenosine production and enhancing immune response
  • ATP recruits various antitumor immune cells to the tumor environment
  • Targeting CD39 shows promise for improving immunotherapy efficacy

Cite This Study

Bi et al. (2026) studied this question.

synapsesocial.com/papers/69fc2ba98b49bacb8b347afdhttps://doi.org/10.1021/acs.jmedchem.6c00078
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunotherapy-related biomarkers: Confirmations and uncertainties2023 · 49 citations
  2. 2Identification of Novel CD39 Inhibitors Based on Virtual Screening and Enzymatic Assays2021 · 13 citations
  3. 3Crystal structure of the nucleotide‐metabolizing enzyme NTPDase42020 · 12 citations
  4. 4The Immune Regulatory Role of Adenosine in the Tumor Microenvironment2023 · 58 citations
  5. 5CD39/CD73/A2AR pathway and cancer immunotherapy2023 · 399 citations